Cost-effectiveness analysis of six strategies for cardiovascular surgery prophylaxis in patients labeled penicillin allergic

被引:24
作者
Phillips, E
Louie, M
Knowles, SR
Simor, AE
Oh, PI
机构
[1] Sunnybrook & Womens Coll, Ctr Hlth Sci, Div Clin Pharmacol, Toronto, ON M4N 3M5, Canada
[2] Sunnybrook & Womens Coll, Ctr Hlth Sci, Dept Microbiol, Toronto, ON M4N 3M5, Canada
[3] Sunnybrook & Womens Coll, Ctr Hlth Sci, Div Infect Dis, Toronto, ON M4N 3M5, Canada
关键词
allergies; antibiotics; cefazolin; cephalosporins; costs; decision making; drugs; adverse reactions; economics; models; penicillin; penicillins; surgery; tests; vancomycin;
D O I
10.1093/ajhp/57.4.339
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The cost-effectiveness of different approaches to antimicrobial prophylaxis for cardiovascular surgery patients labeled penicillin allergic was studied. A decision-analytic model was used to examine the cost-effectiveness of six strategies for antimicrobial prophylaxis in cardiovascular surgery patients at a tertiary care hospital. The strategies consisted of (1) giving vancomycin to all patients labeled penicillin allergic, (2) giving cefazolin to all patients labeled penicillin allergic, (3) giving vancomycin to all patients with a history suggesting an immunoglobulin E (IgE)mediated reaction to penicillin and cefazolin to patients without such a history, (4) administering a penicillin skin test to patients with a history suggesting an IgE-mediated reaction to penicilli? and giving vancomycin to patients with positive results and cefazolin to all others, (5) skin testing all patients labeled penicillin allergic and giving vancomycin to those with positive results and cefazolin to those with negative results regardless of history, and (6) skin testing all patients and giving vancomycin to those with positive results or a history suggesting an IgE-mediated reaction to penicillin and cefazolin to all others. Giving cefazolin to all patients labeled penicillin allergic was:the least expensive strategy but was associated with the highest rate of both anaphylatic and non-life-threatening serious reactions.::Selective use of vancomycin in patients with a history suggesting an IgE-mediated reaction to penicillin was associated with an added cost and a slightly lower rate of anaphylaxis. Although skin-testing strategies: may decrease both non-life-threatening and anaphylactic reactions, the incremental:cost was high. When vancomycin Was given to all patients labeled penicillin allergic, the incremental cost was very high. A decision-analytic model indicated that : selective use of vancomycin is-more cost effective than indiscriminate:use of vancomycin for surgical prophylaxis in cardiovascular surgery patients' labeled penicillin allergic.
引用
收藏
页码:339 / 345
页数:7
相关论文
共 25 条
[1]   ALLERGIC REACTIONS TO BETA-LACTAMS - STUDIES IN A GROUP OF PATIENTS ALLERGIC TO PENICILLIN AND EVALUATION OF CROSS-REACTIVITY WITH CEPHALOSPORIN [J].
AUDICANA, M ;
BERNAOLA, G ;
URRUTIA, I ;
ECHECHIPIA, S ;
GASTAMINZA, G ;
MUNOZ, D ;
FERNANDEZ, E ;
DECORRES, LF .
ALLERGY, 1994, 49 (02) :108-113
[2]   PREVENTING ADVERSE DRUG EVENTS IN HOSPITALIZED-PATIENTS [J].
EVANS, RS ;
PESTOTNIK, SL ;
CLASSEN, DC ;
HORN, SD ;
BASS, SB ;
BURKE, JP .
ANNALS OF PHARMACOTHERAPY, 1994, 28 (04) :523-527
[3]   CLINICAL-EXPERIENCE WITH PENICILLIN SKIN TESTING IN A LARGE INNER-CITY STD CLINIC [J].
GADDE, J ;
SPENCE, M ;
WHEELER, B ;
ADKINSON, NF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (20) :2456-2463
[4]  
HIERHOLZER WJ, 1995, AM J INFECT CONTROL, V23, P87
[5]   Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin [J].
Hiramatsu, K ;
Aritaka, N ;
Hanaki, H ;
Kawasaki, S ;
Hosoda, Y ;
Hori, S ;
Fukuchi, Y ;
Kobayashi, I .
LANCET, 1997, 350 (9092) :1670-1673
[6]   THE CROSS-REACTIVITY AND IMMUNOLOGY OF BETA-LACTAM ANTIBIOTICS [J].
KISHIYAMA, JL ;
ADELMAN, DC .
DRUG SAFETY, 1994, 10 (04) :318-327
[7]   A PERSPECTIVE ON PENICILLIN ALLERGY [J].
LIN, RY .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (05) :930-937
[8]  
MAKI DG, 1992, J THORAC CARDIOV SUR, V104, P1423
[9]  
MANDEL G, 1995, PRINCIPLES PRACTICE
[10]  
MARCUZZI M, 1997, CAN J HOSP PHARM, V50, P96